JP2023500360A5 - - Google Patents
Info
- Publication number
- JP2023500360A5 JP2023500360A5 JP2022526378A JP2022526378A JP2023500360A5 JP 2023500360 A5 JP2023500360 A5 JP 2023500360A5 JP 2022526378 A JP2022526378 A JP 2022526378A JP 2022526378 A JP2022526378 A JP 2022526378A JP 2023500360 A5 JP2023500360 A5 JP 2023500360A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- brain
- item
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076413A JP2025107344A (ja) | 2019-11-04 | 2025-05-01 | Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930473P | 2019-11-04 | 2019-11-04 | |
| US62/930,473 | 2019-11-04 | ||
| PCT/US2020/058905 WO2021092026A1 (en) | 2019-11-04 | 2020-11-04 | Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076413A Division JP2025107344A (ja) | 2019-11-04 | 2025-05-01 | Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500360A JP2023500360A (ja) | 2023-01-05 |
| JP2023500360A5 true JP2023500360A5 (https=) | 2023-11-28 |
Family
ID=75688247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526378A Pending JP2023500360A (ja) | 2019-11-04 | 2020-11-04 | Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 |
| JP2025076413A Pending JP2025107344A (ja) | 2019-11-04 | 2025-05-01 | Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076413A Pending JP2025107344A (ja) | 2019-11-04 | 2025-05-01 | Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210128509A1 (https=) |
| EP (1) | EP4054410A4 (https=) |
| JP (2) | JP2023500360A (https=) |
| CN (1) | CN115515484A (https=) |
| AU (1) | AU2020380291A1 (https=) |
| CA (1) | CA3160283A1 (https=) |
| WO (1) | WO2021092026A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3618824A4 (en) * | 2017-05-02 | 2021-06-23 | Neuronasal, LLC | USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| US12594254B2 (en) * | 2022-02-07 | 2026-04-07 | Neuronasal, Inc. | Intranasal administration of n-acetylcysteine and uses thereof |
| WO2023192691A2 (en) * | 2022-04-01 | 2023-10-05 | Wake Forest University Health Sciences | Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease |
| US20250371713A1 (en) * | 2024-05-28 | 2025-12-04 | Debra Strick Rivera | Mapping glutathione deficiency and/or dysfunction of mitochondria |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010507572A (ja) * | 2006-10-23 | 2010-03-11 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 併用療法 |
| CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| ES2844199T3 (es) * | 2013-04-16 | 2021-07-21 | Childrens Hospital Philadelphia | Composiciones y métodos para el tratamiento de lesiones cerebrales |
| EP3618824A4 (en) * | 2017-05-02 | 2021-06-23 | Neuronasal, LLC | USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| WO2019084543A1 (en) * | 2017-10-27 | 2019-05-02 | Beyond Barriers Therapeutics, Inc. | ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS |
| CA3165422A1 (en) * | 2019-12-18 | 2021-06-24 | Neuronasal, Inc. | Methods of treating brain disorders |
-
2020
- 2020-11-04 AU AU2020380291A patent/AU2020380291A1/en active Pending
- 2020-11-04 EP EP20883931.6A patent/EP4054410A4/en active Pending
- 2020-11-04 CN CN202080091814.4A patent/CN115515484A/zh active Pending
- 2020-11-04 US US17/089,192 patent/US20210128509A1/en not_active Abandoned
- 2020-11-04 JP JP2022526378A patent/JP2023500360A/ja active Pending
- 2020-11-04 CA CA3160283A patent/CA3160283A1/en active Pending
- 2020-11-04 WO PCT/US2020/058905 patent/WO2021092026A1/en not_active Ceased
-
2023
- 2023-04-03 US US18/295,125 patent/US20230321020A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076413A patent/JP2025107344A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500360A5 (https=) | ||
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| JP2023518635A5 (https=) | ||
| Fenelon et al. | Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study | |
| JP2022153638A5 (https=) | ||
| JP2017519807A5 (https=) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JP2020534270A5 (https=) | ||
| JP2023535744A5 (https=) | ||
| JP2020075938A (ja) | 神経精神系障害の治療のための組成物および方法 | |
| CN105327349A (zh) | Nmda受体拮抗剂的医药用途及其药物组合物 | |
| US6384083B1 (en) | Use of adamantane amines or structurally similar compounds for combating borna disease virus and for the prevention and treatment of affective diseases and other disorders associated with bdv infections in humans and animals | |
| JP2002511875A (ja) | 勃起機能障害治療用のヨヒンビンおよびアルギニン含有薬 | |
| Park et al. | Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat | |
| CN113116877A (zh) | L-4-氯犬尿氨酸的剂型和治疗用途 | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| MX2007006825A (es) | Agente preventivo o terapeutico para trastorno del sueno. | |
| JP2023520703A5 (https=) | ||
| US20250288548A1 (en) | Intranasal baclofen | |
| JP2024502466A5 (https=) | ||
| KR20220066985A (ko) | 퇴행성 신경질환의 치료 방법 | |
| RU2318516C2 (ru) | Способ лечения эректильной дисфункции у мужчин | |
| JP2024518426A5 (https=) | ||
| Karabin et al. | The recent guidelines for pharmacotherapy of Parkinson’s Disease | |
| JP2023538859A5 (https=) |